{"id":"NCT02414854","sponsor":"Sanofi","briefTitle":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","officialTitle":"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-27","primaryCompletion":"2017-07-29","completion":"2017-11-23","firstPosted":"2015-04-13","resultsPosted":"2018-10-23","lastUpdate":"2018-10-23"},"enrollment":1902,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["SAR231893","REGN668"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Inhaled corticosteroid (ICS) therapy","otherNames":[]},{"type":"DRUG","name":"Albuterol/Salbutamol","otherNames":[]},{"type":"DRUG","name":"Levalbuterol/Levosalbutamol","otherNames":[]}],"arms":[{"label":"Placebo (for Dupilumab 200 mg) q2w","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab 200 mg q2w","type":"EXPERIMENTAL"},{"label":"Placebo (for Dupilumab 300 mg) q2w","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab 300 mg q2w","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.\n\nSecondary Objectives:\n\n* To evaluate the safety and tolerability of dupilumab.\n* To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.\n* To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.","primaryOutcome":{"measure":"Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Placebo (for Dupilumab 200 mg) q2w","deltaMin":0.871,"sd":null},{"arm":"Dupilumab 200 mg q2w","deltaMin":0.456,"sd":null},{"arm":"Placebo (for Dupilumab 300 mg) q2w","deltaMin":0.97,"sd":null},{"arm":"Dupilumab 300 mg q2w","deltaMin":0.524,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":9},"locations":{"siteCount":389,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Colombia","France","Germany","Hungary","Italy","Japan","Mexico","Poland","Russia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["29782217","40458676","38555079","38013139","37901346","37752621","37659435","37431558","37073882","36535524","36356712","36087550","36028446","35899469","35636689","35487538","35255536","34954123","34752208","34326187","34266940","34181876","34037993","33905544","33481203","33010038","32444306","31521831","31351189","30138668","29725983","29355679"],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed/?term=29782217&report=abstract"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":313},"commonTop":["Viral upper respiratory tract infection","Bronchitis","Upper respiratory tract infection","Injection site erythema","Headache"]}}